FDA pulls back on regulatory demands for Huntington's gene therapy and booming peptide market products
The FDA is pulling back on regulatory demands for certain products it oversees, including a gene therapy for Huntington's disease and the growing peptide market.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near United States
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
G7 leaders call for coordinated response to Ebola outbreak
G7 leaders have called for a coordinated international response to the Ebola outbreak.
Africa CDC chief warns Ebola response faces 'difficult operating environment' as outbreak expands in DRC and Uganda, with 827 cases and 194 deaths recorded
Africa CDC DirectorJean Kaseya warned that the response to the expanding Ebola outbreak in the DRC and Uganda is advancing in a difficult operating environment, with 827 confirmed cases and 194 deaths reported.
US gasoline prices fall below $4 per gallon for first time since March, easing pressure on consumers as fuel costs retreat from spring highs.
US gasoline prices fall below $4 per gallon for the first time since March.
Trump says Apple will work with Intel to manufacture chips in the United States, a potential boost for domestic semiconductor production.
Trump says Apple to work with Intel to manufacture chips in U.S.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.